West Pharma (WST) Declares $0.14 Quarterly Dividend, 0.6% Yield; Announces Up to 800K Share Buyback Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall St set for higher open as AI stocks rise, oil slides
- Streamflation drives 39% of Americans to cancel streaming in 6 months
West Pharma (WST) Tops Q4 EPS by 1c, Slight Miss on Revenues
February 15, 2018 6:02 AM ESTWest Pharma (NYSE: WST) reported Q4 EPS of $0.64, $0.01 better than the analyst estimate of $0.63. Revenue for the quarter came in at $415.6 million versus the consensus estimate of $416.58 million.
Executive Summary
Fourth-quarter 2017 reported net sales of $415.6 million grew 8.7% over the prior-year quarter. At constant currency, organic sales growth was 4.5%. Excluding impacts from the deconsolidation of operations in Venezuela and hurricane-related shutdowns, organic sales growth would have been 6.0%.Full-year 2017... More